EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer

Puwei Song iD, Jianghui Zhou, Kaiqin Wu iD, Wenli Wang iD, Shaorui Gu iD

Mediators of Inflammation · 09.05.2023 · 2023 · 1-27

DOI: 10.1155/2023/9658912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, erschienen am 09.05.2023. Verfasst von Puwei Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tongji Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gefitinib resistance remains a major problem in the treatment of lung cancer. However, the underlying mechanisms involved in gefitinib resistance are largely unclear.

Methods

Open-accessed data of lung cancer patients were downloaded from The Cancer Genome Atlas Program and Gene Expression Omnibus databases. CCK8, colony formation, and 5-ethynyl-2 ′ -deoxyuridine assays were utilized to evaluate the cell proliferation ability. Transwell and wound-healing assays were utilized to evaluate the cell invasion and migration ability. Quantitative real-time PCR was utilized to detect the RNA level of specific genes.

Results

Here, we obtained the expression profile data of wild and gefitinib-resistant cells. Combined with the data from the TCGA and GDSC databases, we identified six genes, RNF150, FAT3, ANKRD33, AFF3, CDH2, and BEX1, that were involved in gefitinib resistance in both cell and tissue levels. We found that most of these genes were expressed in the fibroblast of the NSCLC microenvironment. Hence, we also comprehensively investigated the role of fibroblast in the NSCLC microenvironment, including its biological effect and cell interaction. Ultimately, CDH2 was selected for further analysis for its prognosis correlation. In vitro experiments presented the cancer-promoting role of CDH2 in NSCLC. Moreover, cell viability detection showed that the inhibition of CDH2 could significantly decrease the IC50 of gefitinib in NSCLC cells. GSEA showed that CDH2 could significantly affect the pathway activity of PI3K/AKT/mTOR signaling.

Conclusions

This study is aimed at investigating the underlying mechanism involved in gefitinib resistance to lung cancer. Our research has improved researchers’ understanding of gefitinib resistance. Meanwhile, we found that CDH2 could lead to gefitinib resistance through PI3K/AKT/mTOR signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansGefitinibProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsQuinazolinesDrug Resistance, NeoplasmCell ProliferationTOR Serine-Threonine KinasesCell Line, TumorTumor MicroenvironmentMembrane Proteins

Substanzen

GefitinibAntineoplastic AgentsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsQuinazolinesTOR Serine-Threonine KinasesRNF150 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Thoracic Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.

ORCID-Profile: Puwei Song, Kaiqin Wu, Wenli Wang, Shaorui Gu

Förderung

  • Tongji Hospital

Zitieren

APA

Song, P., Zhou, J., Wu, K., Wang, W., & Gu, S. (2023). The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer. Mediators of Inflammation, 2023, 1-27. https://doi.org/10.1155/2023/9658912

Vancouver

Song P, Zhou J, Wu K, Wang W, Gu S. The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer. Mediators of Inflammation. 2023;2023:1-27. doi:10.1155/2023/9658912

BibTeX
@article{Song2023,
  author = {Song, Puwei and Zhou, Jianghui and Wu, Kaiqin and Wang, Wenli and Gu, Shaorui},
  title = {The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer},
  journal = {Mediators of Inflammation},
  year = {2023},
  volume = {2023},
  pages = {1--27},
  doi = {10.1155/2023/9658912}
}
Kostenlos starten →